Furthermore, polyclonal activated Treg reduced IFN-γ and TNF-α in Teff from DMF-treated MS patients comparable to HC, emphasizing again that DMF restores the responsiveness of Teff for Treg-mediated suppression. The gene discussed is TNF; the disease is myeloid sarcoma.